Stock events for Akebia Therapeutics, Inc. (AKBA)
Over the past six months, Akebia Therapeutics' stock has experienced significant events, including a stock price decline. Key events impacting the stock include Q3 2025 financial results with a year-over-year revenue increase and net income, the decision to refocus Vafseo purely on dialysis patients, Q4 and full-year 2025 financial results with increased net product revenue and reduced net loss, pipeline expansion and milestones, and analyst ratings suggesting a potential upside.
Demand Seasonality affecting Akebia Therapeutics, Inc.’s stock price
Based on the available information, there is no explicit mention of demand seasonality for Akebia Therapeutics' products and services. Demand for its essential medical treatments is typically driven by patient need and disease prevalence rather than seasonal fluctuations.
Overview of Akebia Therapeutics, Inc.’s business
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease. The company's product portfolio includes Vafseo (vadadustat), an oral HIF-PH inhibitor approved for anemia due to CKD in dialysis patients, and Auryxia (ferric citrate), used for controlling serum phosphorus levels in dialysis-dependent CKD patients and treating iron deficiency anemia in non-dialysis-dependent CKD patients. Akebia also has a pipeline of clinical-stage candidates targeting rare kidney diseases and acute kidney injury.
AKBA’s Geographic footprint
Akebia Therapeutics is headquartered in Cambridge, Massachusetts, and has an international presence through Vafseo's approval and commercialization in the United States and 37 other countries. The company also has license and collaboration agreements with partners like Tanabe Pharma Corporation for Vafseo in Japan and other Asian countries.
AKBA Corporate Image Assessment
Akebia Therapeutics has generally maintained a positive brand reputation, particularly concerning its products and pipeline in the kidney disease community. The commercial launch of Vafseo has been met with a positive reception, with expanded brand awareness and comfort in prescribing the drug among nephrologists. The company's strategic focus on addressing unmet medical needs in nephrology through innovative treatment options contributes to its reputation.
Ownership
Akebia Therapeutics has a diverse shareholder base, with institutional investors owning approximately 44.14% to 59.04% of the stock, including major shareholders like BlackRock, Inc., Vanguard Group Inc., and State Street Corp. Individual and retail investors hold approximately 47.71% to 78.60% of the company. Company insiders maintain a notable stake, owning approximately 7.72% to 8.15% of the shares, with Muneer A. Satter being the largest individual shareholder.
